# Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

> **NCT01617213** · PHASE2 · TERMINATED · sponsor: **University of Virginia** · enrollment: 1 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01617213
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2015-04
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study is no longer needed as recent data have answered the primary hypotheses for this study.
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01617213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01617213, "Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01617213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*